Skip to main
CANF

CANF Stock Forecast & Price Target

CANF Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Can Fite Biopharma is expected to achieve commercial success with its pipeline of drugs targeting the A3AR, starting with Namodenoson, which has shown promising results in Phase 2b clinical trials and has the potential to treat a variety of diseases including cancer, inflammatory diseases, and liver disorders. The company's current cash position and partnerships with Gebro Holdings and other global partners provide a strong base for continued development and potential licensing opportunities. However, there are risks associated with commercialization, clinical trials, and regulatory approvals, which should be considered. Nevertheless, based on a risk-adjusted net present value analysis, we see a significant potential for future revenues, leading us to maintain a Buy rating on CANF and raising our 12-month price target to $8.00 per ADS.

Bears say

Can Fite Biopharma is facing a negative outlook due to limited durable treatment options in pancreatic cancer and the need for combination immunotherapy in their pipeline product, as well as the lack of visibility and uncertainty surrounding potential strategic relevance. Additionally, the company's partnership opportunities may not lead to successful collaborations, posing a risk to their program.

CANF has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Can-Fite BioPharma Ltd. (CANF) Forecast

Analysts have given CANF a Strong Buy based on their latest research and market trends.

According to 2 analysts, CANF has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Can-Fite BioPharma Ltd. (CANF)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.